REAL AF: The primary purpose of this registry is to assess procedural safety and long-term effectiveness of RF ablations in the treatment of patients with paroxysmal and persistent atrial fibrillation. The registry will utilize real world clinical data obtained from the use of commercially available novel RF technologies under the authority of a health care practitioner within a legitimate practitioner-patient relationship.

Oceanic AF: This Phase 3 study will explore asundexian 50 mg once daily to determine lower risk for bleeding as well as an improved efficacy in terms of reduction of thromboembolic events when compared with apixaban (NOAC) in patients with AF at risk for stroke.

Pivatal: To prospectively evaluate the effect of prophylactic intra-operative ventricular tachyarrhythmia ablation (VTA) at the time of left ventricular assist device (LVAD) implantation on post-implant total recurrent VTA events, after accounting for the competing risk of death, from discharge to an average follow-up of 18 months (with a minimum of 9 months) after LVAD implantation

AdaptiveCRT: The purpose of this study is to determine if Cardiac Resynchronization Therapy (CRT), may be beneficial for subjects that are experiencing a decrease in the pumping ability in their heart.  A new feature called Adaptive CRT (aCRT) that attempts to automatically optimize CRT in subjects’ CRT D devices.  The aCRT feature observes patterns in your heart’s contractions and then automatically adjusts your CRT D device to optimize CRT for you without echo testing.